Can-Fite BioPharma (CANF) Earnings Date, Estimates & Call Transcripts → Gold Mania (From Stansberry Research) (Ad) Free CANF Stock Alerts $2.09 +0.06 (+2.96%) (As of 05/3/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsSocial Media Earnings SummaryLatest Earnings DateMar. 28EstimatedActual EPS (Mar. 28) -$0.31 Missed By -$0.04 Consensus EPS (Mar. 28) -$0.27 Get Can-Fite BioPharma Earnings AlertsEnter your email address below to receive the latest news and earnings results for CANF and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueCANF Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CANF Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Stansberry ResearchGold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. Can-Fite BioPharma Analyst EPS EstimatesCurrent Year EPS Consensus Estimate:($0.03) EPSCANF Earnings Date and InformationCan-Fite BioPharma last issued its quarterly earnings data on March 28th, 2024. The reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.27) by $0.04. The business had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.20 million. Can-Fite BioPharma has generated ($1.79) earnings per share over the last year (($1.79) diluted earnings per share). Read More Can-Fite BioPharma Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript3/28/2024Q4 2023($0.27)($0.31)($0.04)($0.31)$0.20 million$0.16 million11/30/2023Q3 2023($0.43)($0.43)-($0.43)$0.20 million$0.20 million8/31/2023Q2 2023($0.54)($0.40)+$0.14($0.40)$0.20 million$0.20 million6/1/2023Q1 2023-($0.65)($0.65)($0.65)-$0.20 million6/1/2023Q1 2023-($0.65)($0.65)($0.65)-$0.20 million6/1/2023Q1 2023-($0.65)($0.65)($0.65)-$0.20 million Get the Latest News and Ratings for CANF and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Can-Fite BioPharma and its competitors with MarketBeat's FREE daily newsletter. 6/1/2023Q1 2023-($0.65)($0.65)($0.65)-$0.20 million6/1/2023Q1 2023-($0.65)($0.65)($0.65)-$0.20 million6/1/2023Q1 2023-($0.65)($0.65)($0.65)-$0.20 million6/1/2023Q1 2023-($0.65)($0.65)($0.65)-$0.20 million6/1/2023Q1 2023-($0.65)($0.65)($0.65)-$0.20 million6/1/2023Q1 2023-($0.65)($0.65)($0.65)-$0.20 million6/1/2023Q1 2023-($0.65)($0.65)($0.65)-$0.20 million6/1/2023Q1 2023-($0.65)($0.65)($0.65)-$0.20 million6/1/2023Q1 2023-($0.65)($0.65)($0.65)-$0.20 million6/1/2023Q1 2023-($0.65)($0.65)($0.65)-$0.20 million6/1/2023Q1 2023-($0.65)($0.65)($0.65)-$0.20 million6/1/2023Q1 2023-($0.65)($0.65)($0.65)-$0.20 million6/1/2023Q1 2023-($0.65)($0.65)($0.65)-$0.20 million6/1/2023Q1 2023-($0.65)($0.65)($0.65)-$0.20 million6/1/2023Q1 2023-($0.65)($0.65)($0.65)-$0.20 million6/1/2023Q1 2023-($0.65)($0.65)($0.65)-$0.20 million3/30/2023Q4 2022($0.57)($1.11)($0.54)($1.11)$0.50 million$0.20 million3/30/2023Q4 2022($0.57)($1.11)($0.54)($1.11)$0.50 million$0.20 million3/30/2023Q4 2022($0.57)($1.11)($0.54)($1.11)$0.50 million$0.20 million3/30/2023Q4 2022($0.57)($1.11)($0.54)($1.11)$0.50 million$0.20 million3/30/2023Q4 2022($0.57)($1.11)($0.54)($1.11)$0.50 million$0.20 million3/30/2023Q4 2022($0.57)($1.11)($0.54)($1.11)$0.50 million$0.20 million3/30/2023Q4 2022($0.57)($1.11)($0.54)($1.11)$0.50 million$0.20 million3/30/2023Q4 2022($0.57)($1.11)($0.54)($1.11)$0.50 million$0.20 million3/30/2023Q4 2022($0.57)($1.11)($0.54)($1.11)$0.50 million$0.20 million3/30/2023Q4 2022($0.57)($1.11)($0.54)($1.11)$0.50 million$0.20 million3/30/2023Q4 2022($0.57)($1.11)($0.54)($1.11)$0.50 million$0.20 million3/30/2023Q4 2022($0.57)($1.11)($0.54)($1.11)$0.50 million$0.20 million3/30/2023Q4 2022($0.57)($1.11)($0.54)($1.11)$0.50 million$0.20 million3/30/2023Q4 2022($0.57)($1.11)($0.54)($1.11)$0.50 million$0.20 million3/30/2023Q4 2022($0.57)($1.11)($0.54)($1.11)$0.50 million$0.20 million3/30/2023Q4 2022($0.57)($1.11)($0.54)($1.11)$0.50 million$0.20 million3/30/2023Q4 2022($0.57)($1.11)($0.54)($1.11)$0.50 million$0.20 million3/30/2023Q4 2022($0.57)($1.11)($0.54)($1.11)$0.50 million$0.20 millionAutomatic Income (from home) (Ad)For over 22 years, Wall Street elites have kept this little-known "income hack" from everyday investors… 6 simple clicks have set up HUGE payouts for "in-the-know" investors… Delivering them passive income 365 days a year. Just click here now to watch my presentation for free.3/30/2023Q4 2022($0.57)($1.11)($0.54)($1.11)$0.50 million$0.20 million3/30/2023Q4 2022($0.57)($1.11)($0.54)($1.11)$0.50 million$0.20 million11/25/2022Q3 2022($1.00)($0.90)+$0.10($0.90)$0.40 million$0.20 million11/25/2022Q3 2022($1.00)($0.90)+$0.10($0.90)$0.40 million$0.20 million11/25/2022Q3 2022($1.00)($0.90)+$0.10($0.90)$0.40 million$0.20 million11/25/2022Q3 2022($1.00)($0.90)+$0.10($0.90)$0.40 million$0.20 million11/25/2022Q3 2022($1.00)($0.90)+$0.10($0.90)$0.40 million$0.20 million11/25/2022Q3 2022($1.00)($0.90)+$0.10($0.90)$0.40 million$0.20 million11/25/2022Q3 2022($1.00)($0.90)+$0.10($0.90)$0.40 million$0.20 million11/25/2022Q3 2022($1.00)($0.90)+$0.10($0.90)$0.40 million$0.20 million11/25/2022Q3 2022($1.00)($0.90)+$0.10($0.90)$0.40 million$0.20 million11/25/2022Q3 2022($1.00)($0.90)+$0.10($0.90)$0.40 million$0.20 million11/25/2022Q3 2022($1.00)($0.90)+$0.10($0.90)$0.40 million$0.20 million11/25/2022Q3 2022($1.00)($0.90)+$0.10($0.90)$0.40 million$0.20 million11/25/2022Q3 2022($1.00)($0.90)+$0.10($0.90)$0.40 million$0.20 million11/25/2022Q3 2022($1.00)($0.90)+$0.10($0.90)$0.40 million$0.20 million11/25/2022Q3 2022($1.00)($0.90)+$0.10($0.90)$0.40 million$0.20 million11/25/2022Q3 2022($1.00)($0.90)+$0.10($0.90)$0.40 million$0.20 million11/25/2022Q3 2022($1.00)($0.90)+$0.10($0.90)$0.40 million$0.20 million11/25/2022Q3 2022($1.00)($0.90)+$0.10($0.90)$0.40 million$0.20 million11/25/2022Q3 2022($1.00)($0.90)+$0.10($0.90)$0.40 million$0.20 million11/25/2022Q3 2022($1.00)($0.90)+$0.10($0.90)$0.40 million$0.20 million11/25/2022Q3 2022($1.00)($0.90)+$0.10($0.90)$0.40 million$0.20 million8/25/2022Q2 2022($0.90)($0.80)+$0.10($0.80)$0.30 million$0.20 million8/25/2022Q2 2022($0.90)($0.80)+$0.10($0.80)$0.30 million$0.20 million8/25/2022Q2 2022($0.90)($0.80)+$0.10($0.80)$0.30 million$0.20 million8/25/2022Q2 2022($0.90)($0.80)+$0.10($0.80)$0.30 million$0.20 million8/25/2022Q2 2022($0.90)($0.80)+$0.10($0.80)$0.30 million$0.20 million8/25/2022Q2 2022($0.90)($0.80)+$0.10($0.80)$0.30 million$0.20 million8/25/2022Q2 2022($0.90)($0.80)+$0.10($0.80)$0.30 million$0.20 million8/25/2022Q2 2022($0.90)($0.80)+$0.10($0.80)$0.30 million$0.20 million8/25/2022Q2 2022($0.90)($0.80)+$0.10($0.80)$0.30 million$0.20 million8/25/2022Q2 2022($0.90)($0.80)+$0.10($0.80)$0.30 million$0.20 million8/25/2022Q2 2022($0.90)($0.80)+$0.10($0.80)$0.30 million$0.20 million8/25/2022Q2 2022($0.90)($0.80)+$0.10($0.80)$0.30 million$0.20 million8/25/2022Q2 2022($0.90)($0.80)+$0.10($0.80)$0.30 million$0.20 million8/25/2022Q2 2022($0.90)($0.80)+$0.10($0.80)$0.30 million$0.20 million8/25/2022Q2 2022($0.90)($0.80)+$0.10($0.80)$0.30 million$0.20 million8/25/2022Q2 2022($0.90)($0.80)+$0.10($0.80)$0.30 million$0.20 million8/25/2022Q2 2022($0.90)($0.80)+$0.10($0.80)$0.30 million$0.20 million8/25/2022Q2 2022($0.90)($0.80)+$0.10($0.80)$0.30 million$0.20 million8/25/2022Q2 2022($0.90)($0.80)+$0.10($0.80)$0.30 million$0.20 million8/25/2022Q2 2022($0.90)($0.80)+$0.10($0.08)$0.30 million$0.20 million8/25/2022Q2 2022($0.09)($0.08)+$0.01($0.08)$0.30 million$0.20 million5/26/2022Q1 2022($0.12)($0.09)+$0.03($0.09)$0.20 million$0.21 million5/26/2022Q1 2022($1.20)($0.90)+$0.30($0.09)$0.20 million$0.21 million5/26/2022Q1 2022($1.20)($0.90)+$0.30($0.90)$0.20 million$0.21 million5/26/2022Q1 2022($1.20)($0.90)+$0.30($0.90)$0.20 million$0.21 million5/26/2022Q1 2022($1.20)($0.90)+$0.30($0.90)$0.20 million$0.21 million5/26/2022Q1 2022($1.20)($0.90)+$0.30($0.90)$0.20 million$0.21 millionElon’s New Device is About to Shock the World (Ad)Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake.5/26/2022Q1 2022($1.20)($0.90)+$0.30($0.90)$0.20 million$0.21 million5/26/2022Q1 2022($1.20)($0.90)+$0.30($0.90)$0.20 million$0.21 million5/26/2022Q1 2022($1.20)($0.90)+$0.30($0.90)$0.20 million$0.21 million5/26/2022Q1 2022($1.20)($0.90)+$0.30($0.90)$0.20 million$0.21 million5/26/2022Q1 2022($1.20)($0.90)+$0.30($0.90)$0.20 million$0.21 million5/26/2022Q1 2022($1.20)($0.90)+$0.30($0.90)$0.20 million$0.21 million5/26/2022Q1 2022($1.20)($0.90)+$0.30($0.90)$0.20 million$0.21 million5/26/2022Q1 2022($1.20)($0.90)+$0.30($0.90)$0.20 million$0.21 million5/26/2022Q1 2022($1.20)($0.90)+$0.30($0.90)$0.20 million$0.21 million5/26/2022Q1 2022($1.20)($0.90)+$0.30($0.90)$0.20 million$0.21 million5/26/2022Q1 2022($1.20)($0.90)+$0.30($0.90)$0.20 million$0.21 million5/26/2022Q1 2022($1.20)($0.90)+$0.30($0.90)$0.20 million$0.21 million5/26/2022Q1 2022($1.20)($0.90)+$0.30($0.90)$0.20 million$0.21 million5/26/2022Q1 2022($1.20)($0.90)+$0.30($0.90)$0.20 million$0.21 million5/26/2022Q1 2022($1.20)($0.90)+$0.30($0.90)$0.20 million$0.21 million3/24/2022Q4 2021($1.80)($1.90)($0.10)($1.90)$0.30 million$0.20 million3/24/2022Q4 2021($1.80)($1.90)($0.10)($1.90)$0.30 million$0.20 million3/24/2022Q4 2021($1.80)($1.90)($0.10)($1.90)$0.30 million$0.20 million3/24/2022Q4 2021($1.80)($1.90)($0.10)($1.90)$0.30 million$0.20 million3/24/2022Q4 2021($1.80)($1.90)($0.10)($1.90)$0.30 million$0.20 million3/24/2022Q4 2021($1.80)($1.90)($0.10)($1.90)$0.30 million$0.20 million3/24/2022Q4 2021($1.80)($1.90)($0.10)($1.90)$0.30 million$0.20 million3/24/2022Q4 2021($1.80)($1.90)($0.10)($1.90)$0.30 million$0.20 million3/24/2022Q4 2021($1.80)($1.90)($0.10)($1.90)$0.30 million$0.20 million3/24/2022Q4 2021($1.80)($1.90)($0.10)($1.90)$0.30 million$0.20 million3/24/2022Q4 2021($1.80)($1.90)($0.10)($0.19)$0.30 million$0.20 million3/24/2022Q4 2021($1.80)($1.90)($0.10)($1.90)$0.30 million$0.20 million3/24/2022Q4 2021($1.80)($1.90)($0.10)($1.90)$0.30 million$0.20 million3/24/2022Q4 2021($1.80)($1.90)($0.10)($1.90)$0.30 million$0.20 million3/24/2022Q4 2021($1.80)($1.90)($0.10)($1.90)$0.30 million$0.20 million3/24/2022Q4 2021($1.80)($1.90)($0.10)($1.90)$0.30 million$0.20 million3/24/2022Q4 2021($1.80)($1.90)($0.10)($1.90)$0.30 million$0.20 million3/24/2022Q4 2021($1.80)($1.90)($0.10)($1.90)$0.30 million$0.20 million3/24/2022Q4 2021($1.80)($1.90)($0.10)($1.90)$0.30 million$0.20 million3/24/2022Q4 2021($1.80)($1.90)($0.10)($1.90)$0.30 million$0.20 million3/24/2022Q4 2021($0.18)($0.19)($0.01)($0.19)$0.30 million$0.20 million11/30/2021Q3 2021($0.90)($1.90)($1.00)($0.19)-$0.25 million11/26/2021Q3 2021($1.00)($1.90)($0.90)($1.90)-$0.25 million11/26/2021Q3 2021($1.00)($1.90)($0.90)($1.90)-$0.25 million11/26/2021Q3 2021($1.00)($1.90)($0.90)($1.90)-$0.25 million11/26/2021Q3 2021($1.00)($1.90)($0.90)($1.90)-$0.25 million11/26/2021Q3 2021($1.00)($1.90)($0.90)($1.90)-$0.25 million11/26/2021Q3 2021($1.00)($1.90)($0.90)($1.90)-$0.25 million11/26/2021Q3 2021($1.00)($1.90)($0.90)($1.90)-$0.25 million11/26/2021Q3 2021($1.00)($1.90)($0.90)($1.90)-$0.25 million11/26/2021Q3 2021($1.00)($1.90)($0.90)($1.90)-$0.25 million11/26/2021Q3 2021($1.00)($1.90)($0.90)($1.90)-$0.25 million11/26/2021Q3 2021($0.10)($0.19)($0.09)($0.19)-$0.25 million11/26/2021Q3 2021($1.00)($1.90)($0.90)($1.90)-$0.25 million11/26/2021Q3 2021($1.00)($1.90)($0.90)($1.90)-$0.25 millionElon’s New Device is About to Shock the World (Ad)Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake.11/26/2021Q3 2021($1.00)($1.90)($0.90)($1.90)-$0.25 million11/26/2021Q3 2021($1.00)($1.90)($0.90)($1.90)-$0.25 million11/26/2021Q3 2021($1.00)($1.90)($0.90)($1.90)-$0.25 million11/26/2021Q3 2021($1.00)($1.90)($0.90)($1.90)-$0.25 million11/26/2021Q3 2021($1.00)($1.90)($0.90)($1.90)-$0.25 million11/26/2021Q3 2021($1.00)($1.90)($0.90)($1.90)-$0.25 million11/26/2021Q3 2021($1.00)($1.90)($0.90)($1.90)-$0.25 million8/26/2021Q2 2021($1.20)($1.90)($0.70)($1.90)$0.30 million$0.25 million8/26/2021Q2 2021($1.20)($1.90)($0.70)($1.90)$0.30 million$0.25 million8/26/2021Q2 2021($1.20)($1.90)($0.70)($1.90)$0.30 million$0.25 million8/26/2021Q2 2021($1.20)($1.90)($0.70)($1.90)$0.30 million$0.25 million8/26/2021Q2 2021($1.20)($1.90)($0.70)($1.90)$0.30 million$0.25 million8/26/2021Q2 2021($1.20)($1.90)($0.70)($1.90)$0.30 million$0.25 million8/26/2021Q2 2021($1.20)($1.90)($0.70)($1.90)$0.30 million$0.25 million8/26/2021Q2 2021($1.20)($1.90)($0.70)($1.90)$0.30 million$0.25 million8/26/2021Q2 2021($1.20)($1.90)($0.70)($1.90)$0.30 million$0.25 million8/26/2021Q2 2021($1.20)($1.90)($0.70)($1.90)$0.30 million$0.25 million8/26/2021Q2 2021($1.20)($1.90)($0.70)($1.90)$0.30 million$0.25 million8/26/2021Q2 2021($1.20)($1.90)($0.70)($1.90)$0.30 million$0.25 million8/26/2021Q2 2021($1.20)($1.90)($0.70)($1.90)$0.30 million$0.25 million8/26/2021Q2 2021($1.20)($1.90)($0.70)($1.90)$0.30 million$0.25 million8/26/2021Q2 2021($1.20)($1.90)($0.70)($1.90)$0.30 million$0.25 million8/26/2021Q2 2021($1.20)($1.90)($0.70)($1.90)$0.30 million$0.25 million8/26/2021Q2 2021($1.20)($1.90)($0.70)($1.90)$0.30 million$0.25 million8/26/2021Q2 2021($1.20)($1.90)($0.70)($1.90)$0.30 million$0.25 million8/26/2021Q2 2021($1.20)($1.90)($0.70)($1.90)$0.30 million$0.25 million8/26/2021Q2 2021($1.20)($1.90)($0.70)($0.19)$0.30 million$0.25 million8/26/2021Q2 2021($0.12)($0.19)($0.07)($0.19)$0.30 million$0.25 million5/27/2021Q1 2021($0.17)($0.12)+$0.05($0.12)$0.30 million$0.15 million5/27/2021Q1 2021($1.70)($1.20)+$0.50($0.12)$0.30 million$0.15 million5/27/2021Q1 2021($1.70)($1.20)+$0.50($1.20)$0.30 million$0.15 million5/27/2021Q1 2021($1.70)($1.20)+$0.50($1.20)$0.30 million$0.15 million5/27/2021Q1 2021($1.70)($1.20)+$0.50($1.20)$0.30 million$0.15 million5/27/2021Q1 2021($1.70)($1.20)+$0.50($1.20)$0.30 million$0.15 million5/27/2021Q1 2021($1.70)($1.20)+$0.50($1.20)$0.30 million$0.15 million5/27/2021Q1 2021($1.70)($1.20)+$0.50($1.20)$0.30 million$0.15 million5/27/2021Q1 2021($1.70)($1.20)+$0.50($1.20)$0.30 million$0.15 million5/27/2021Q1 2021($1.70)($1.20)+$0.50($1.20)$0.30 million$0.15 million5/27/2021Q1 2021($1.70)($1.20)+$0.50($1.20)$0.30 million$0.15 million5/27/2021Q1 2021($1.70)($1.20)+$0.50($1.20)$0.30 million$0.15 million5/27/2021Q1 2021($1.70)($1.20)+$0.50($1.20)$0.30 million$0.15 million5/27/2021Q1 2021($1.70)($1.20)+$0.50($1.20)$0.30 million$0.15 million5/27/2021Q1 2021($1.70)($1.20)+$0.50($1.20)$0.30 million$0.15 million5/27/2021Q1 2021($1.70)($1.20)+$0.50($1.20)$0.30 million$0.15 million5/27/2021Q1 2021($1.70)($1.20)+$0.50($1.20)$0.30 million$0.15 million5/27/2021Q1 2021($1.70)($1.20)+$0.50($1.20)$0.30 million$0.15 million5/27/2021Q1 2021($1.70)($1.20)+$0.50($1.20)$0.30 million$0.15 million5/27/2021Q1 2021($1.70)($1.20)+$0.50($1.20)$0.30 million$0.15 million5/27/2021Q1 2021($1.70)($1.20)+$0.50($1.20)$0.30 million$0.15 million Can-Fite BioPharma Earnings - Frequently Asked Questions When did Can-Fite BioPharma announce their last quarterly earnings? Can-Fite BioPharma (NYSE:CANF) last announced its quarterly earning data on Thursday, March 28, 2024. Learn more on CANF's earnings history. Did Can-Fite BioPharma beat their earnings estimates last quarter? In the previous quarter, Can-Fite BioPharma (NYSE:CANF) missed the analysts' consensus estimate of ($0.27) by $0.04 with a reported earnings per share (EPS) of ($0.31). Learn more on analysts' earnings estimate vs. CANF's actual earnings. How much revenue does Can-Fite BioPharma generate each year? Can-Fite BioPharma (NYSE:CANF) has a recorded annual revenue of $740,000.00. How much profit does Can-Fite BioPharma generate each year? Can-Fite BioPharma (NYSE:CANF) has a recorded net income of -$7.63 million. CANF has generated -$1.79 earnings per share over the last four quarters. More Earnings Resources from MarketBeat Related Companies: BRTX Earnings NAVB Earnings EIGR Earnings GLTO Earnings EFTR Earnings HEPA Earnings CMMB Earnings CVKD Earnings TRVN Earnings VCNX Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Apple’s Earnings Show Investors Its Strength and Its WeaknessCarvana’s Q1 Earnings: A Profitability U-TurnPayPal’s Strong Earnings Growth and Strategic Evolution GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future OutlookCSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings? This page (NYSE:CANF) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldCharles Payne Demystifies OptionsUnstoppable ProsperityThe asset beating inflation by 4xColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
